Business
Bioasis and WuXi Biologics Announce Initial Strategic Collaboration for the Development and Manufacturing of xB3-001, the Company’s Lead Investigational Candidate to Treat Brain Cancer
Bioasis and WuXi Biologics Announce Initial Strategic Collaboration for the Development and Manufacturing of xB3-001, the Company’s Lead Investigational Candidate to Treat Brain Cancer.
About this update from Bioasis Technologies Inc.
[{"type":"text","content":"\n \n BIOASIS \n TECHNOLOGIES INC. (TSX.V:BTI; OTCQB:BIOAF) and WUXI \n BIOLOGICS (2269.HK) today announced an initial strategic \n collaboration for the development and manufacturing of xB3-001, \n Bioasis’ lead investigational biological candidate to treat brain cancer.\n \n\nThis press release features multimedia. View the full release here: \nhttps://www.businesswire.com/news/home/20180521005460/en/\n\n\n \n Bioasis is a biopharmaceutical company developing xB3, a \n proprietary platform technology for the delivery of therapeutics across \n the blood-brain barrier (BBB) and the treatment of CNS disorders in \n areas of high unmet medical-need, including brain cancers and \n neurodegenerative diseases.\n \n \n Headquartered in Wuxi city, Jiangsu province, China, WuXi Biologics is a \n leading global platform company providing end-to-end solutions for \n biologics with a mission to accelerate and transform biologics \n discovery, development and manufacturing to benefit patients around the \n world.\n \n \n “The initiation of manufacturing for xB3-001 is a pivotal \n milestone for Bioasis as we look to advance our lead program in HER2+ \n breast cancer brain metastases,” said Mark Day, Ph.D., president and \n chief executive officer, Bioasis. “WuXi Biologics’ expertise and \n experience in manufacturing biologics is instrumental to Bioasis in \n developing our pipeline.”\n \n \n The delivery of most biologics across the BBB and into the brain has \n been the single greatest challenge to treating brain diseases. Bioasis \n is engineering its first biologic product candidate, xB3-001, \n to overcome this obstacle in brain cancer. Manufacturing these \n sophisticated therapies requires a tailor-made approach, with expertise \n and agility in cell line, process and formulation development.\n \n \n “We are excited to take on this work with Bioasis to enable them \n bringing innovative therapies to patients suffering from brain cancer,” \n said Dr. Chris Chen, chief executive officer, WuXi Biologics. “This \n collaboration allows us to leverage our expertise across biological drug \n development and anticipate Bioasis’ needs as they move from pre-clinical \n to clinical and beyond.”\n \n \n Through this partnership Bioasis will have access to WuXi Biologics&...